Keyword: Acorda Therapeutics
Acorda’s share price took a one-two punch this week, with the FDA extending review of its drug-device treatment for Parkinson’s disease by 3 months.
Acorda's chief technology officer Rick Batycky, Ph.D., is leaving the company next week after four years in the role to head up his own operation.
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
The action marks the end for an oral adenosine A2a receptor antagonist Acorda paid $363 million in cash for last year.
Shares in Acorda Therapeutics are sliding following the news that the company’s Parkinson’s drug has been linked to a potentially fatal side effect.
Canaan will continuw the strategy that has delivered it paydays as companies including J&J and Teva have snapped up pieces of its portfolio.
Acorda was up 10% early yesterday on the posting of late-stage data for certain Parkinson’s patients, but then fell during the day.
A phase 3 clinical trial of Acorda Therapeutics’ inhaled formulation of levodopa has met its primary endpoint.
Acorda’s poststroke walking difficulties med dalfampridine doesn’t work, and the biotech is pulling the plug as it looks across to its Parkinson’s and migraine assets going forward.
Acorda’s three-year comeback effort on the epilepsy treatment Plumiaz has ended in failure.